Table 3.
Clinical intervention and outcomes based on PESI risk stratification*
| Variable | Total (N = 101) | PESI ≤ 85 (n = 35) | PESI > 85 (n = 66) | P value |
|---|---|---|---|---|
| Anticoagulation: Heparin Enoxaparin Argatroban Direct oral anticoagulant |
25 (25%) 69 (69%) 4 (4%) 3 (3%) |
4 (11%) 29 (83%) 1 (3%) 1 (3%) |
21 (31%) 40 (60%) 4 (5%) 3 (4%) |
0.084 |
| Thrombolytic use: Full dose Half dose |
3 (3%) 2 (2%) |
1 (3%) 0 |
2 (3%) 2 (3%) |
0.794 |
| Transfusion | 9 (9%) | 3 (9%) | 6 (9%) | 0.621 |
| Renal replacement therapy | 1 (1%) | 0 | 1 (2%) | 0.653 |
| Intensive care unit admission | 23 (23%) | 4 (11%) | 19 (29%) | 0.038 |
| Mechanical Ventilation | 20 (20%) | 4 (11%) | 16 (24%) | 0.099 |
| Length of hospital stay, days† | 13.0 (± 10.2) | 9.7 (± 5.4) | 14.3 (± 11.6) | 0.030 |
| Acute kidney injury | 31 (31%) | 7 (20%) | 24 (36%) | 0.069 |
| Bleeding: Severe Moderate |
7 (7%) 5 (5%) |
2 (6%) 1 (3%) |
5 (8%) 4 (5%) |
0.893 |
| Deep Venous Thromboembolism | 13 (13%) | 3 (9%) | 10 (15%) | 0.347 |
| Stroke‡ | 3 (3%) | 0 | 3 (4%) | 0.257 |
| Mortality | 20 (20%) | 2 (6%) | 18 (27%) | 0.007 |
⁎
Values are presented as no (%) or mean (± standard deviation) where applicable.
†
At the final study follow-up date, 6 patients remain admitted in the hospital.
‡
All 3 patients had acute hemorrhagic stroke and, thus, were also accounted for under severe bleeding events.